Kura Oncology Inc

Kura Oncology Inc has a market capitalization of $987.93 million and a price-to-book ratio of 5.67, indicating a premium valuation relative to its book value. The company holds $149.10 million in cash and equivalents, while its total liabilities amount to $564.23 million, with long-term debt at $9.71 million. The current ratio of 6.06 suggests strong short-term liquidity, with the company's assets significantly outpacing its liabilities. The company reported a net loss of $278.67 million for the period, with an operating loss of $303.63 million. Return on equity (ROE) is negative at -1.60, and return on assets (ROA) is also negative at -0.38, indicating poor profitability relative to its equity and asset base. Gross profit of $67.43 million is nearly equal to total revenue of $67.48 million, suggesting minimal cost of goods sold, but this is offset by high operating expenses. Kura Oncology Inc's revenue is not segmented by geographic region or product line in the available data, but the company operates in the biotechnology sector, which is typically driven by innovation and clinical trial progress rather than geographic diversification. The company's revenue concentration is not disclosed, but its operations are likely centered in the United States, as is common for biotechnology firms. The company's revenue growth is not explicitly forecasted, but the negative operating cash flow of $64.06 million and free cash flow of -$284.27 million indicate ongoing cash burn. Capital expenditures of -$6.64 million suggest minimal investment in physical assets, with the company likely allocating capital to research and development. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.06 is low, and its cash reserves are substantial relative to its liabilities. However, the negative net income and operating cash flow suggest ongoing financial pressure, and the company may need to raise additional capital in the future. Recent analyst estimates show a mean price target of $31.17, with a median of $28.00 and a high of $76.00, indicating a wide range of expectations. The mean recommendation of 1.88 (on a scale of 1 to 5) suggests a generally positive outlook among analysts, with 4 strong-buy ratings and 10 buy ratings.